Blue Water Biotech is a biotechnology company focused on the research and development of transformational vaccines to prevent infectious diseases worldwide. Co.'s vaccine platform has molecular properties that enables delivery of various antigens, which can be utilized to develop singular or multi-targeted vaccines. Co.'s lead influenza (flu) vaccine program uses proprietary technology to identify specific epitopes, or proteins, with cross-reactive properties that enables the potential development of a universal flu vaccine. Co.'s lead vaccine candidates, BWV-101 and BWV-102, are being investigated as a universal influenza vaccine with the potential against all influenza strains. The BWV average annual return since 2022 is shown above.
The Average Annual Return on the BWV average annual return since 2022 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether BWV average annual return since 2022 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the BWV average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|